Status:
ACTIVE_NOT_RECRUITING
Long Term Beta Thalassemia Treatment: Findings From The Extension Period
Lead Sponsor:
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Conditions:
Fetal Hemoglobin
Beta-Thalassemia
Eligibility:
All Genders
8-35 years
Phase:
PHASE2
Brief Summary
The project, titled "Long Term Beta Thalassemia Treatment: Findings From The Extension Period Of Phase 2 Clinical Trial," aims to compare the efficacy and safety of combination therapy (thalidomide an...
Detailed Description
Study titled Long Term Beta Thalassemia Treatment: Findings From The Extension Period Of Phase 2 Clinical Trial, conducted at the National Institute of Blood Disease \& Bone Marrow Transplantation (NI...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Known case of beta thalassemia major/intermediate (transfusion dependent)
- Willing to give informed consent
- Exclusion Criteria
- Patients with comorbidities such as liver dysfunction
- Married patients
- Lactating mothers
- History of thrombosis and fits
Exclusion
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06490601
Start Date
April 1 2022
End Date
July 1 2025
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of blood disease and bone marrow transplant
Karachi, Sindh, Pakistan